Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
Aug 15 (Reuters) - AstraZeneca said a late-stage trial had confirmed the benefit of breast cancer drug Enhertu in patients with an advanced form of the disease who had been previously treated with another therapy.
Read more
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their Enhertu drug met its primary endpoint in a breast cancer trial.
Read more(Alliance News) - Stock prices in London are seen opening higher on Monday, though equities in China were showing signs of late weakness after poorer than expected retail sales data from the world's second-largest economy.
Read more
(Sharecast News) - Drugmaker AstraZeneca said on Monday that positive high-level results from a new trial of its Enhertu breast cancer drug had demonstrating a "statistically significant and clinically meaningful improvement" in progression-free survival.
Read more(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Friday said their drug conjugate Enhertu has been approved for patients in the US with unresectable or metastatic non-small cell lung cancer.
Read more(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu drug has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer, the companies said on Friday.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said results from a trial showed promising clinical activity in patients with non-small cell lung cancer.
Read more(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials.
Read more(Sharecast News) - AstraZeneca's breast cancer treatment candidate 'Enhertu', or trastuzumab deruxtecan, has been approved in the United States, it announced on Monday.
Read more(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said their drug conjugate Enhertu has been approved for more patients in the US.
Read moreLONDON, Aug 8 (Reuters) - With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.
Read moreLONDON, Aug 5 (Reuters) - AstraZeneca and Daiichi Sankyo on Friday secured U.S. approval that broadens the use of their therapy Enhertu, for patients with breast cancer, and paves the way for billions in sales.
Read moreLONDON, Aug 5 (Reuters) - AstraZeneca and Daiichi Sankyo have secured faster-than-expected U.S. approval for their drug, Enhertu, in patients with a particular form of breast cancer.
Read moreAstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Says new tablet formulation of Calquence, whose generic name is acalabrutinib, has been approved in the US for all current indications. These include adult patients with chronic lymphocytic leukaemia, the most prevalent type of leukaemia in adults, and with blood cancer small lymphocytic lymphoma; and for patients with relapsed or refractory mantle cell lymphoma, an uncommon subtype of B-cell non-Hodgkin lymphoma. AstraZeneca says the approval by the US Food & Drug Administration was based on the Elevate-Plus trials, conducted in 116 healthy subjects.
Read moreJOHANNESBURG, Aug 4 (Reuters) - South Africa's health regulator reported on Thursday a causal link between the death of an individual and Johnson & Johnson's (J&J) COVID-19 vaccine, the first time such a direct link has been made in the country.
Read more
Last checked at